115 related articles for article (PubMed ID: 2367753)
1. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes.
Daemen T; Dontje BH; Veninga A; Scherphof GL; Oosterhuis WL
Sel Cancer Ther; 1990; 6(2):63-71. PubMed ID: 2367753
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy of murine liver metastases with 5-fluorouracil in combination with liposome-encapsulated muramyl dipeptide.
Daemen T; Dontje BH; Regts J; Scherphof GL
J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):31-5. PubMed ID: 8435429
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
Phillips NC; Tsao MS
Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
[TBL] [Abstract][Full Text] [Related]
4. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.
Phillips NC; Tsao MS
Cancer Immunol Immunother; 1991; 33(2):85-90. PubMed ID: 2036662
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.
Brodt P; Blore J; Phillips NC; Munzer JS; Rioux JD
Cancer Immunol Immunother; 1989; 28(1):54-8. PubMed ID: 2909283
[TBL] [Abstract][Full Text] [Related]
6. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin.
Asao T; Shibata HR; Batist G; Brodt P
Cancer Res; 1992 Nov; 52(22):6254-7. PubMed ID: 1423270
[TBL] [Abstract][Full Text] [Related]
7. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
Phillips NC; Rioux J; Tsao MS
Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.
BubenÃk J; Jezek J; Zaoral M; Hofmann J; Gruntenko YV; Osipov JG; Zolotareva AG; Vakhrusheva TE; Budker VG
Cancer Immunol Immunother; 1984; 18(2):123-5. PubMed ID: 6568871
[TBL] [Abstract][Full Text] [Related]
9. Liposomal phosphatidylserine inhibits tumor cytotoxicity of liver macrophages induced by muramyl dipeptide and lipopolysaccharide.
Daemen T; Regts J; Scherphof GL
Biochim Biophys Acta; 1996 Dec; 1285(2):219-28. PubMed ID: 8972706
[TBL] [Abstract][Full Text] [Related]
10. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis of murine candidiasis via application of liposome-encapsulated amphotericin B and a muramyl dipeptide analog, alone and in combination.
Mehta RT; Lopez-Berestein G; Hopfer RL; Mehta K; White RA; Juliano RL
Antimicrob Agents Chemother; 1985 Oct; 28(4):511-3. PubMed ID: 4073873
[TBL] [Abstract][Full Text] [Related]
12. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
13. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.
Fidler IJ; Sone S; Fogler WE; Barnes ZL
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1680-4. PubMed ID: 6940181
[TBL] [Abstract][Full Text] [Related]
14. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
15. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
[TBL] [Abstract][Full Text] [Related]
16. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.
Fidler IJ; Barnes Z; Fogler WE; Kirsh R; Bugelski P; Poste G
Cancer Res; 1982 Feb; 42(2):496-501. PubMed ID: 7055801
[TBL] [Abstract][Full Text] [Related]
17. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell binding and induction of endothelial cell tumoricidal activity in vitro by muramyl dipeptide is enhanced by liposomal encapsulation.
Phillips NC; Stewart-Phillips J; Wang P
J Immunother Emphasis Tumor Immunol; 1994 Apr; 15(3):185-93. PubMed ID: 8032541
[TBL] [Abstract][Full Text] [Related]
19. In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide.
Daemen T; Veninga A; Roerdink FH; Scherphof GL
Cancer Res; 1986 Sep; 46(9):4330-5. PubMed ID: 3731091
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster.
Nitta Y; Sugita T; Ikuta Y; Murakami T
Oncol Res; 2000; 12(1):25-31. PubMed ID: 11061343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
